Evidence map›Paper›PMID 40715574›Full record

ArticleFamilial cancer2025

MLH1 c.27G>A (p.Arg9=) is a synonymous likely/pathogenic variant underlying variably mosaic constitutional MLH1 methylation in Lynch syndrome.

Rocio Alvarez, Paula Climent-Cantó, GiWon Shin, Francesca Paola Aguirre, Lisa Zhou, Dennis J Hazelett, Brent K Larson, Covadonga Vara, Gabriel Capellá, Víctor Lorca Castellanos and 8 more

Abstract readCase Reports
In one paragraph

Article in Familial cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rocio Alvarez *Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Paula Climent-Cantó *Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908, Barcelona, Spain.
GiWon Shin *Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Francesca Paola AguirreDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Lisa ZhouDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Dennis J HazelettDepartment of Computational Biology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Brent K LarsonDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Covadonga VaraHereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908, Barcelona, Spain.
Gabriel CapelláHereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908, Barcelona, Spain.
Víctor Lorca CastellanosLaboratorio de Oncología Molecular, IdISSC, Hospital Clínico San Carlos, 28040, Madrid, Spain.
Pilar Garre RubioMolecular Diagnosis Unit, Clinical Analysis Department, IML, IdISSC, Hospital Clínico San Carlos, 28040, Madrid, Spain.
Françoise DesseigneLeon Berard Center, Clinical Oncogenetics Unit, Lyon, France.
Hanlee JiDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Jackie CookSheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield, UK.
Miranda Durkie *Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield, UK.
Marta Pineda *Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908, Barcelona, Spain.
Julie Leclerc *CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France.
Megan P Hitchins *Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Megan.Hitchins@moffitt.org.ORCID 0000-0002-3603-2309

Funding

The mechanistic basis for constitutional MLH1 methylation (epimutation)R01CA218342 · NCI · CEDARS-SINAI MEDICAL CENTER · PI HITCHINS, MEGAN P · 2019 to 2022
$1.9M
Instituto de Salud Carlos III and European Regional Development FEDER PI19/01336NCI NIH HHS R01 CA218342Spanish Ministry of Science PID2019-111254RB-I00 and PID2023-151585OB-I00USA National Cancer Institute R01CA218342
6 · The paper itself

Abstract

The MLH1 synonymous variant c.27G>A (p.Arg9 =) has been reported in four index cases with suspected Lynch syndrome, but is variably classified as "likely pathogenic" or "variant of uncertain significance" due to insubstantial clinical and functional evidence. We report three new MLH1 c.27G>A index cases with family histories fulfilling Amsterdam criteria for Lynch syndrome and reassessed collective evidence for pathogenicity. Two are European families from the UK (two siblings) and Spain (three members spanning three generations), and the third is a proband from Mongolia, the first non-European reported with this variant. Blood-based constitutional MLH1 methylation testing in six heterozygotes from the three families revealed varying levels of mosaic methylation, even within the same family, ranging from extremely low (≤ 1%) to ~ 16%. Two heterozygotes with blood methylation ≤ 1% had elevated methylation (5-8%) in normal colon distant from their colon cancers. Mosaic constitutional MLH1 methylation was linked in cis to the variant c.27A allele in all six heterozygotes and segregated together across generations. Three archived early-onset colon cancers available from three heterozygotes (UK siblings, Mongolian proband) each displayed MLH1 loss, MLH1 hypermethylation, and loss-of-heterozygosity of the wild-type c.27G allele, consistent with methylated c.27A alleles within a fraction of colon cells predisposing to tumorigenesis. Nanopore sequencing in the two European families found no significant shared ancestry and no other candidate variants. Multifactorial data collated from these and prior observational studies now provide sufficient evidence for the classification of MLH1 c.27G>A as likely/pathogenic via a functional mechanism of variably mosaic "secondary" constitutional MLH1 epimutation.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisDNA MethylationMosaicismMutL Protein Homolog 1AdultFemaleHeterozygoteHumansMaleMiddle AgedPedigreeMLH1 protein, humanMutL Protein Homolog 1Lynch syndromeMosaicismSecondary constitutional MLH1 epimutation

Identifiers

PMID40715574
PMCPMC12330223

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.